These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18690928)

  • 21. A Pharmacoepidemiology Database System for Monitoring Risk Due to the Use of Medicines by New Zealand Primary Care Patients.
    Tomlin AM; Reith DM; Woods DJ; Lloyd HS; Smith A; Fountain JS; Tilyard MW
    Drug Saf; 2017 Dec; 40(12):1259-1277. PubMed ID: 28766108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
    Perrio MJ; Wilton LV; Shakir SA
    Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of primary care prescribing rates for new drugs on spontaneous reporting of adverse drug reactions.
    Clark RC; Maxwell SR; Kerr S; Cuthbert M; Buchanan D; Steinke D; Webb DJ; Bateman ND
    Drug Saf; 2007; 30(4):357-66. PubMed ID: 17408312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-marketing surveillance in New Zealand.
    Edwards IR
    Med Toxicol; 1986; 1 Suppl 1():83-5. PubMed ID: 3821432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of a Web-Based, 'Purchase Event' Intensive Monitoring Method for Pharmacovigilance of Natural Health Products: Lessons and Insights from Development Work in New Zealand.
    Barnes J; Sheridan JL; Dong CY; Härmark L; Vohra S; Harrison-Woolrych M
    Drug Saf; 2020 Oct; 43(10):981-998. PubMed ID: 32596765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Nordic prescription databases as a resource for pharmacoepidemiological research--a literature review.
    Wettermark B; Zoëga H; Furu K; Korhonen M; Hallas J; Nørgaard M; Almarsdottir A; Andersen M; Andersson Sundell K; Bergman U; Helin-Salmivaara A; Hoffmann M; Kieler H; Martikainen J; Mortensen M; Petzold M; Wallach-Kildemoes H; Wallin C; Sørensen H
    Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):691-9. PubMed ID: 23703712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacoepidemiology and its input to pharmacovigilance.
    Faillie JL; Montastruc F; Montastruc JL; Pariente A
    Therapie; 2016 Apr; 71(2):211-6. PubMed ID: 27080840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiooedema and urticaria with angiotensin converting enzyme inhibitors.
    Pillans PI; Coulter DM; Black P
    Eur J Clin Pharmacol; 1996; 51(2):123-6. PubMed ID: 8911875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).
    Beggs PW; Clark DW; Williams SM; Coulter DM
    Br J Clin Pharmacol; 1999 Jan; 47(1):99-104. PubMed ID: 10073746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database.
    Ståhl M; Lindquist M; Edwards IR; Brown EG
    Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):355-63. PubMed ID: 15170764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
    Kasliwal R; Layton D; Harris S; Wilton L; Shakir SA
    Drug Saf; 2005; 28(9):803-16. PubMed ID: 16119973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug metabolism genotypes and their association with adverse drug reactions in selected populations: a pilot study of methodology.
    Clark D; Morgan A; Hananeia L; Coulter D; Olds R
    Pharmacoepidemiol Drug Saf; 2000 Sep; 9(5):393-400. PubMed ID: 19025845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital.
    Mendes D; Rigueiro G; Silva RS; Penedones A; Alves C; Sousa G; Batel-Marques F
    J Oncol Pharm Pract; 2020 Jan; 26(1):133-140. PubMed ID: 31117914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts.
    Olsson S
    Drug Saf; 1998 Jul; 19(1):1-10. PubMed ID: 9673854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profile of adverse events in patients receiving treatment for malaria in urban Ghana: a cohort-event monitoring study.
    Dodoo AN; Fogg C; Nartey ET; Ferreira GL; Adjei GO; Kudzi W; Sulley AM; Kodua A; Ofori-Adjei D
    Drug Saf; 2014 Jun; 37(6):433-48. PubMed ID: 24788801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring New Zealand prescription data using sequence symmetry analyses for predicting adverse drug reactions.
    Nishtala PS; Chyou TY
    J Clin Pharm Ther; 2017 Apr; 42(2):189-194. PubMed ID: 27957745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring the Potential Routine Use of Electronic Healthcare Record Data to Strengthen Early Signal Assessment in UK Medicines Regulation: Proof-of-Concept Study.
    Donegan K; Owen R; Bird H; Burch B; Smith A; Tregunno P
    Drug Saf; 2018 Sep; 41(9):899-910. PubMed ID: 29725942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.
    Layton D; Wilton LV; Shakir SA
    Eur J Clin Pharmacol; 2004 Sep; 60(7):489-501. PubMed ID: 15278327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.